Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.48 |
| ▸ | NPC1 | O15118 | 5/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 7/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.43 |
| ▸ | JAK1 | P23458 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22445968 | 0.96 | RAB9A (0.47) | RAB9ANPC1KDM4ESMN1; SMN2MEN1 | |
| SCHEMBL22445882 | 0.85 | LRRK2 (0.45) | RAB9AKDM4ELRRK2JAK2JAK1 | |
| SCHEMBL22445883 | 0.79 | JAK2 (0.44) | RAB9AKDM4ELRRK2JAK2JAK1 | |
| SCHEMBL22453111 | 0.74 | LRRK2 (0.42) | LRRK2JAK2JAK1 | |
| SCHEMBL22889932 | 0.72 | LRRK2 (0.70) | LRRK2 | |
| SCHEMBL22445841 | 0.72 | LRRK2 (0.70) | RAB9ANPC1LRRK2JAK2JAK1 | |
| SCHEMBL22445904 | 0.72 | LRRK2 (0.43) | RAB9AKDM4ELRRK2JAK2JAK1 | |
| SCHEMBL18167981 | 0.72 | JAK2 (0.52) | LRRK2JAK2JAK1 | |
| SCHEMBL22445917 | 0.71 | ULK1 (0.48) | RAB9ANPC1SMN1; SMN2KMT2ALRRK2 | |
| SCHEMBL12286618 | 0.71 | JAK2 (0.63) | SMN1; SMN2MEN1KMT2ALRRK2JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | ESCAPE Bio, Inc. | 2022-05-26 | — | — | US | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191261-A1 | INDAZOLES AS LRRK2 INHIBITORS | E-SCAPE BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220162192-A1 | INDAZOLES AS LRRK2 INHIBITORS | LRRK2, PARK7, PINK1 | RAB9A 164/4885NPC1 123/4885KDM4E 2393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.